Since 1987, no new class of human antibiotics have come on to the market. Our new class of antibiotic has been synthesised using a unique and economic method of manufacture. Unlike current antibiotics, which rely on a specific ‘lock and key fit’ between the antibiotic and the bacteria causing the disease, our antibiotics have been designed to overcome this shortfall, starting at the process of our patented antibiotic synthesis.
How our unique antibiotics targets superbugs
RECCE® 327 non-specifically attacks protein in the outer wall of bacteria. Their unique pressure within causes them to burst and lose viability. The protein may mutate as in a superbug; however, as it is still protein, as usual, the RECCE® antibiotics still attack it. Whether it is the normal or superbug form of the bacteria, RECCE® antibiotics still kills it. Application of RECCE® 327 initially weakens the cell walls of the bacteria and almost immediately, the cell wall begins to collapse or burst, resulting in bacterial cell death.
Electron microscope images generated by Dr Peta Clode and Lyn Kirilak of the Centre for Microscopy, Characterisation and Analysis, University of Western Australia, demonstrate RECCE® 327’s unique mechanism of action.
RECCE® 327 – Mechanism of Action